3‐O‐methyldopa administration does not alter fluorodopa transport into the brain

Mark Guttman, Gabriel Léger, Jesse M. Cedarbaum, Avinoam Reches, William Woodward, Alan Evans, Mirko Diksic, Albert Gjedde

Research output: Contribution to journalArticlepeer-review

42 Scopus citations


To determine if 3‐O‐methyldopa (3OMd) significantly inhibits the transport of 6‐{18F} fluorodopa (6‐FD) into the brain at the concentration normally encountered during L‐dopa administration, we performed 6‐FD studies with positron emission tomography in cynomolgus monkeys in the presence and absence of 3OMd. Infusion of 3OMd was designed to produce plasma concentrations equivalent to those seen in patients on chronic L‐dopa therapy. Plasma 3OMd levels of 39 ± μM did not alter the blood–brain transfer rate of 6‐FD. 6‐FD positron emission tomographic studies in parkinsonian patients will therefore not be altered by 3OMd present in the blood in those patients taking L‐dopa preparations. These results do not support the hypothesis that transport of L‐dopa into the brain is inhibited by 3OMd to cause the declining response seen in patients with advanced Parkinson's disease.

Original languageEnglish (US)
Pages (from-to)638-643
Number of pages6
JournalAnnals of Neurology
Issue number6
StatePublished - Jun 1992

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology


Dive into the research topics of '3‐O‐methyldopa administration does not alter fluorodopa transport into the brain'. Together they form a unique fingerprint.

Cite this